Please assess the completion status of the following clinical trial:

Trial Title: A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18-30 Non-smoker for at least 4 weeks~Exclusion Criteria:~* Any clinically relevant acute or chronic disease~* History of substance abuse Hypersensitivity to ketamine

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AZD6765 75 mg (Type: EXPERIMENTAL): None
- AZD6765 150 mg (Type: EXPERIMENTAL): None
- Ketamine 0.5 mg/kg (Type: ACTIVE_COMPARATOR): None
- 125 mL sterile NaCl 0.9% (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).